Suppressors of cytokine signaling abrogate diabetic nephropathy

Journal of the American Society of Nephrology

Volumn 21, Issue 5, 2010, Pages 763-772

  Ortiz Muñoz, Guadalupe ^a   Lopez Parra, Virginia ^a   Lopez Franco, Oscar ^a   Fernandez Vizarra, Paula ^a   Mallavia, Beñat ^a   Flores, Claudio ^b   Sanz, Ana ^a   Blanco, Julia ^c   Mezzano, Sergio ^b   Ortiz, Alberto ^a   Egido, Jesus ^a   Gomez Guerrero, Carmen ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b UNIVERSIDAD AUSTRAL DE CHILE   (Chile)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; GLUCOSE; GROWTH FACTOR; JANUS KINASE; SCLEROPROTEIN; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MACROPHAGE; MALE; MESANGIUM; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES;

EID: 77952556246     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2009060625     Document Type: Article

References (46)

1. Forbes JM, Fukami K, Cooper ME: Diabetic nephropathy: Where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 115: 69-84, 2007
2. Schrijvers BF, De Vriese AS, Flyvbjerg A: From hyperglycemia to diabetic kidney disease: The role of metabolic, hemodynamic, intracellular factors and growth factors/cytokines. Endocr Rev 25: 971-1010, 2004
3. Williams MD, Nadler JL: Inflammatory mechanisms of diabetic complications. Curr Diab Rep 7: 242-248, 2007
4. Navarro-Gonzalez JF, Mora-Fernandez C: The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol 19: 433-442, 2008
5. Ha H, Yu MR, Choi YJ, Kitamura M, Lee HB: Role of high glucoseinduced nuclear factor-kappaB activation in monocyte chemoattractant protein-1 expression by mesangial cells. J Am Soc Nephrol 13: 894-902, 2002
6. Huang JS, Chuang LY, Guh JY, Huang YJ, Hsu MS: Antioxidants attenuate high glucose-induced hypertrophic growth in renal tubular epithelial cells. Am J Physiol Renal Physiol 293: F1072-F1082, 2007
7. Weigert C, Sauer U, Brodbeck K, Pfeiffer A, Haring HU, Schleicher ED: AP-1 proteins mediate hyperglycemia-induced activation of the human TGF-beta1 promoter in mesangial cells. J Am Soc Nephrol 11: 2007-2016, 2000
8. Nangaku M: Mechanisms of tubulointerstitial injury in the kidney: Final common pathways to end-stage renal failure. Intern Med 43: 9-17, 2004
9. Brosius FC, III: New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 9: 245-254, 2008
10. Wang X, Shaw S, Amiri F, Eaton DC, Marrero MB: Inhibition of the JAK/STAT signaling pathway prevents the high glucose-induced increase in tgf-beta and fibronectin synthesis in mesangial cells. Diabetes 51: 3505-3509, 2002
11. Amiri F, Shaw S, Wang X, Tang J, Waller JL, Eaton DC, Marrero MB: Angiotensin II activation of the JAK/STAT pathway in mesangial cells is altered by high glucose. Kidney Int 61: 1605-1616, 2002
12. Marrero MB, Banes-Berceli AK, Stern DM, Eaton DC: Role of the JAK/STAT signaling pathway in diabetic nephropathy. Am J Physiol Renal Physiol 290: F762-F768, 2006
13. Shi YH, Zhao S, Wang C, Li Y, Duan HJ: Fluvastatin inhibits activation of JAK and STAT proteins in diabetic rat glomeruli and mesangial cells under high glucose conditions. Acta Pharmacol Sin 28: 1938-1946, 2007
14. O'Sullivan LA, Liongue C, Lewis RS, Stephenson SE, Ward AC: Cytokine receptor signaling through the JAK-STAT-SOCS pathway in disease. Mol Immunol 44: 2497-2506, 2007
15. Yoshimura A, Naka T, Kubo M: SOCS proteins, cytokine signaling and immune regulation. Nat Rev Immunol 7: 454-465, 2007
16. Rakesh K, Agrawal DK: Controlling cytokine signaling by constitutive inhibitors. Biochem Pharmacol 70: 649-657, 2005
17. Wormald S, Zhang JG, Krebs DL, Mielke LA, Silver J, Alexander WS, Speed TP, Nicola NA, Hilton DJ: The comparative roles of suppressor of cytokine signaling-1 and -3 in the inhibition and desensitization of cytokine signaling. J Biol Chem 281: 11135-11143, 2006
18. Hernandez-Vargas P, Lopez-Franco O, Sanjuan G, Ruperez M, Ortiz- Munoz G, Suzuki Y, Guado-Roncero P, Perez-Tejerizo G, Blanco J, Egido J, Ruiz-Ortega M, Gomez-Guerrero C: Suppressors of cytokine signaling regulate angiotensin II-activated Janus kinase-signal trans- ducers and activators of transcription pathway in renal cells. J Am Soc Nephrol 16: 1673-1683, 2005
19. Soriano SF, Hernanz-Falcon P, Rodriguez-Frade JM, De Ana AM, Garzon R, Carvalho-Pinto C, Vila-Coro AJ, Zaballos A, Balomenos D, Martinez A, Mellado M: Functional inactivation of CXC chemokine receptor 4-mediated responses through SOCS3 up-regulation. J Exp Med 196: 311-321, 2002
20. Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, Blanco J, Egido J: Suppressors of cytokine signaling regulate Fc receptor signaling and cell activation during immune renal injury. J Immunol 172: 6969-6977, 2004
21. Ortiz-Munoz G, Martin-Ventura JL, Hernandez-Vargas P, Mallavia B, Lopez-Parra V, Lopez-Franco O, Munoz-Garcia B, Fernandez-Vizarra P, Ortega L, Egido J, Gomez-Guerrero C: Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis. Arterioscler Thromb Vasc Biol 29: 525-531, 2009
22. de Prati AC, Ciampa AR, Cavalieri E, Zaffini R, Darra E, Menegazzi M, Suzuki H, Mariotto S: STAT1 as a new molecular target of anti-inflammatory treatment. Curr Med Chem 12: 1819-1828, 2005
23. Grote K, Luchtefeld M, Schieffer B: JANUS under stress-Role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 43: 357-363, 2005
24. Berthier CC, Zhang H, Schin M, Henger A, Nelson RG, Yee B, Boucherot A, Neusser MA, Cohen CD, Carter-Su C, Argetsinger LS, Rastaldi MP, Brosius FC, Kretzler M: Enhanced expression of Janus kinasesignal transducer and activator of transcription pathway members in human diabetic nephropathy. Diabetes 58: 469-477, 2009
25. Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, Marrero MB: Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. Am J Physiol Renal Physiol 286: F653-F659, 2004
26. Banes-Berceli AK, Shaw S, Ma G, Brands M, Eaton DC, Stern DM, Fulton D, Caldwell RW, Marrero MB: Effect of simvastatin on high glucose- and angiotensin II-induced activation of the JAK/STAT pathway in mesangial cells. Am J Physiol Renal Physiol 291: F116-F121, 2006
27. Shi Y, Zhang Y, Wang C, Du C, Zhao S, Qi Z, Zhang Q, Duan H: Suppressor of cytokine signaling-1 reduces high glucose-induced TGF-beta1 and fibronectin synthesis in human mesangial cells. FEBS Lett 582: 3484-3488, 2008
28. Lu TC, Wang ZH, Feng X, Chuang PY, Fang W, Shen Y, Levy DE, Xiong H, Chen N, He JC: Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int 76: 63-71, 2009
29. Neria F, Castilla MA, Sanchez RF, Gonzalez Pacheco FR, Deudero JJ, Calabia O, Tejedor A, Manzarbeitia F, Ortiz A, Caramelo C: Inhibition of JAK2 protects renal endothelial and epithelial cells from oxidative stress and cyclosporin A toxicity. Kidney Int 75: 227-234, 2009
30. Mezzano S, Aros C, Droguett A, Burgos ME, Ardiles L, Flores C, Schneider H, Ruiz-Ortega M, Egido J: NF-kappaB activation and overexpression of regulated genes in human diabetic nephropathy. Nephrol Dial Transplant 19: 2505-2512, 2004
31. Sanchez-Nino MD, Sanz AB, Ihalmo P, Lassila M, Holthofer H, Mezzano S, Aros C, Groop PH, Saleem MA, Mathieson PW, Langham R, Kretzler M, Nair V, Lemley KV, Nelson RG, Mervaala E, Mattinzoli D, Rastaldi MP, Ruiz-Ortega M, Martin-Ventura JL, Egido J, Ortiz A: The MIF receptor CD74 in diabetic podocyte injury. J Am Soc Nephrol 20: 353-362, 2009
32. Okada S, Shikata K, Matsuda M, Ogawa D, Usui H, Kido Y, Nagase R, Wada J, Shikata Y, Makino H: Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52: 2586-2593, 2003
33. Chow FY, Nikolic-Paterson DJ, Ozols E, Atkins RC, Rollin BJ, Tesch GH: Monocyte chemoattractant protein-1 promotes the development of diabetic renal injury in streptozotocin-treated mice. Kidney Int 69: 73-80, 2006
34. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, Komiya S, Kosai K, Hanakawa Y, Hashimoto K, Nagata K, Yoshimura A: Induction of the cytokine signal regulator SOCS3/CIS3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest 108: 1781-1788, 2001
35. Adhikari N, Charles N, Lehmann U, Hall JL: Transcription factor and kinase-mediated signaling in atherosclerosis and vascular injury. Curr Atheroscler Rep 8: 252-260, 2006
36. Raghavendra R, V, Bowen KK, Dhodda VK, Song G, Franklin JL, Gavva NR, Dempsey RJ: Gene expression analysis of spontaneously hypertensive rat cerebral cortex following transient focal cerebral ischemia. J Neurochem 83: 1072-1086, 2002
37. Rastmanesh MM, Bluyssen HA, Joles JA, Boer P, Willekes N, Braam B: Increased expression of SOCS3 in monocytes and SOCS1 in lymphocytes correlates with progressive loss of renal function and cardiovascular risk factors in chronic kidney disease. Eur J Pharmacol 593: 99-104, 2008
38. Lebrun P, Van OE: SOCS proteins causing trouble in insulin action. Acta Physiol (Oxf) 192: 29-36, 2008
39. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, Takeda K, Akira S, Matsumoto S, Toyonaga A, Sata M, Yoshimura A: CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med 193: 471-481, 2001
40. Wong PK, Egan PJ, Croker BA, O'Donnell K, Sims NA, Drake S, Kiu H, McManus EJ, Alexander WS, Roberts AW, Wicks IP: SOCS-3 negatively regulates innate and adaptive immune mechanisms in acute IL-1-dependent inflammatory arthritis. J Clin Invest 116: 1571-1581, 2006
41. Egan PJ, Lawlor KE, Alexander WS, Wicks IP: Suppressor of cytokine signaling-1 regulates acute inflammatory arthritis and T cell activation. J Clin Invest 111: 915-924, 2003
42. Barral AM, Thomas HE, Ling EM, Darwiche R, Rodrigo E, Christen U, Ejrnaes M, Wolfe T, Kay TW, von Herrath MG: SOCS-1 protects from virally-induced CD8 T cell mediated type 1 diabetes. J Autoimmun 27: 166-173, 2006
43. Veenbergen S, Bennink MB, de Hooge AS, Arntz OJ, Smeets RL, van den Berg WB, van de Loo FA: Splenic suppressor of cytokine signaling 3 transgene expression affects T cell responses and prevents development of collagen-induced arthritis. Arthritis Rheum 58: 3742-3752, 2008
44. Sakurai H, Tashiro K, Kawabata K, Yamaguchi T, Sakurai F, Nakagawa S, Mizuguchi H: Adenoviral expression of suppressor of cytokine signaling- 1 reduces adenovirus vector-induced innate immune responses. J Immunol 180: 4931-4938, 2008
45. Ahmed CM, Dabelic R, Waiboci LW, Jager LD, Heron LL, Johnson HM: SOCS-1 mimetics protect mice against lethal poxvirus infection: identification of a novel endogenous antiviral system. J Virol 83: 1402-1415, 2009
46. Xiong J, Wang SM, Chen LH, Lin Y, Zhu YF, Ye CS: Elastic fibers reconstructed using adenovirus-mediated expression of tropoelastin and tested in the elastase model of abdominal aortic aneurysm in rats. J Vasc Surg 48: 965-973, 2008